Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Common Equity (2016 - 2025)

Historic Common Equity for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $4.2 million.

  • Champions Oncology's Common Equity rose 52129.22% to $4.2 million in Q4 2025 from the same period last year, while for Oct 2025 it was $4.2 million, marking a year-over-year increase of 52129.22%. This contributed to the annual value of $3.8 million for FY2025, which is 29821.33% up from last year.
  • Latest data reveals that Champions Oncology reported Common Equity of $4.2 million as of Q4 2025, which was up 52129.22% from $3.5 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Common Equity ranged from a high of $9.2 million in Q1 2022 and a low of -$2.1 million during Q1 2024
  • Moreover, its 5-year median value for Common Equity was $5.1 million (2023), whereas its average is $4.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first crashed by 14104.83% in 2024, then soared by 116566.27% in 2025.
  • Over the past 5 years, Champions Oncology's Common Equity (Quarter) stood at $8.1 million in 2021, then increased by 13.64% to $9.2 million in 2022, then tumbled by 98.99% to $93000.0 in 2023, then soared by 632.26% to $681000.0 in 2024, then surged by 521.29% to $4.2 million in 2025.
  • Its Common Equity was $4.2 million in Q4 2025, compared to $3.5 million in Q3 2025 and $3.8 million in Q2 2025.